WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359) released its 2026 third-quarter report, posting Q3 operating revenue of RMB 16.640 billion, up 38.01% year on year (YoY), and net profit attributable to shareholders excluding non-recurring gains and losses of RMB 5.905 billion, up 49.85% YoY. For the first three quarters, revenue totaled RMB 45.537 billion (+38.59% YoY) with adjusted net profit of RMB 16.477 billion (+73.03% YoY), as the company raised its full-year guidance across revenue, capital expenditure, and free cash flow.
Chemistry Dominance:WuXi Chemistry contributed roughly 86% of 9M segment revenue with 51.52% growth, underscoring the strength of the company’s small-molecule CRDMO franchise.
Testing Momentum:WuXi Testing (+31.97%) outgrew WuXi Biology (+12.35%), reflecting continued demand across analytical and clinical testing services.
Raised Full-Year 2026 Guidance
Metric
Previous Guidance
New Guidance
Total Revenue
RMB 58.5–60.5 billion
RMB 61.0–61.9 billion
Continuing Operations Revenue Growth (YoY)
35%–39%
40%–42%
Capital Expenditure
RMB 7.5–8.5 billion
RMB 8.0–8.5 billion
Adjusted Free Cash Flow
RMB 13.5–14.5 billion
RMB 14.5–15.5 billion
Market Impact & Outlook
Guidance Upgrade Signal: Raising both the revenue range and the growth corridor to 40%–42% — alongside a higher adjusted free cash flow outlook — signals management confidence in sustaining the current demand trajectory into year-end.
Backlog Visibility: The RMB 76.74 billion backlog, up 36.4% YoY, provides substantial revenue visibility for 2027 and suggests broad-based customer commitment across the CRDMO platform.
Cash Generation Strength: Adjusted free cash flow guidance of RMB 14.5–15.5 billion, even with capex nudged higher to RMB 8.0–8.5 billion, reflects the capital efficiency of the integrated end-to-end model.
Profit Leverage: Adjusted net profit growing 73.03% against 38.59% revenue growth in 9M demonstrates significant operating leverage and mix shift toward higher-margin chemistry services.
Forward‑Looking Statements This brief contains forward‑looking statements regarding WuXi AppTec’s full-year 2026 guidance, backlog conversion, capital expenditure plans, and free cash flow expectations. Actual results may differ due to risks including global demand fluctuations for pharmaceutical R&D services, geopolitical and regulatory developments affecting cross-border business, foreign-exchange movements, and execution of capacity expansion.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
